DrugBiological
Lepirudin clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 1998 (1)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2002 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
National Institutes of Health Clinical Center (CC) (1) · Dartmouth-Hitchcock Medical Center (1) · Heinrich-Heine University, Duesseldorf (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lepirudin is read from its arms, and is right about nine times in ten.
Testing it · 3
- Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung CancerTerminatedPhase 1/2Dartmouth-Hitchcock Medical CenterNCT00003726Written as lepirudin
- Argatroban Versus Lepirudin in Critically Ill PatientsTerminatedPhase 4Heinrich-Heine University, DuesseldorfNCT00798525Written as Lepirudin
- Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access DevicesCompletedPhase 2National Institutes of Health Clinical Center (CC)NCT00039767Written as Lepirudin
As the comparator · 1 — what is tested is compared with lepirudin
Codes
What other systems call lepirudin · ClinicalTrials.gg INT003750
- MeSH (NLM) C083544lepirudinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y43GF64R34LEPIRUDINConfirmed FDA, NLM
- RxNorm 237057One source FDA
- NCI Thesaurus C1839LepirudinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C083544 | lepirudin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y43GF64R34 | LEPIRUDIN | Confirmed FDA, NLM |
| RxNorm | 237057 | — | One source FDA |
| NCI Thesaurus | C1839 | Lepirudin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.